NSCLC therapy options after first-line treatment
Fewer than 50% of patients in clinical trials receive second line therapy.
Survival benefits with Tarceva
Tarceva maintenance therapy significantly prolonged progression-free survival and overall survival without deteriorating quality of life.
Tarceva.com
This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit www.tarceva.com.
